stars 1 stars 2 stars 3

ProteinLogic has developed a novel technology platform (ImmiPrint®) focused on the diagnosis of tuberculosis (TB). Along with HIV/AIDS, TB is the most significant infectious disease worldwide. Early and accurate diagnosis is essential for its control. The ImmiPrint® platform has the potential to deliver an effective blood-based TB diagnostic, and to provide information on disease progression. The test may also be able to predict which individuals are likely to respond to anti-microbial therapy.

ProteinLogic Ltd Questions

The ProteinLogic Ltd annual revenue was $4 million in 2026.

The NAICS codes for ProteinLogic Ltd are [541713, 541, 5417, 54171, 54].

The SIC codes for ProteinLogic Ltd are [87, 873].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users